FDA official logo
GSRS logo
PFDA official logo

SUTIMLIMAB

  • UNII: GNWE7KJ995
  • Preferred Substance Name: SUTIMLIMAB

  • 2049079-64-1
  • BIVV009
  • BIVV-009
  • ENJAYMO
  • IMMUNOGLOBULIN G4, ANTI-(HUMAN COMPLEMENT C1S) (HUMANIZED MOUSE MONOCLONAL TNT009 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL TNT009 .KAPPA.-CHAIN, DIMER
  • IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS COMPLEMENT C1S SUBCOMPONENT (C1 ESTERASEEC=3.4.21.42)) HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-445) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*03 (90%) (IGHD)-IGHJ4*01) (8.8.11) (1-118)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(226)), CH2(L5>E(233)) (119-445)), (132-216')-DISULFIDE WITH .KAPPA. CHIMERIC LIGHT CHAIN (1'-216') (V-KAPPA (MUS MUSCULUS IGKV4-74*01 (83%)/HOMO SAPIENS IGKV3D-7*01 (78%) IGKJ2*01) (7.3.10) (1'-109')-HOMO SAPIENS IGKC*01 (110'-216')), DIMER (224-224'':227-227'')-BISDISULFIDE
  • SUTIMLIMAB [INN]
  • SUTIMLIMAB [JAN]
  • SUTIMLIMAB [USAN]
  • SUTIMLIMAB [WHO-DD]
  • SUTIMLIMAB JOME [WHO-DD]
  • SUTIMLIMAB-JOME
  • TNT009
  • TNT-009

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.